Breaking Down NeuroPace: 6 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
NeuroPace (NASDAQ:NPCE) has received mixed analyst ratings over the past quarter, with a recent shift towards a more bullish outlook. The average 12-month price target is now $9.67, up 27.24% from the previous $7.60, with a high estimate of $12.00 and a low of $8.00. Analysts from firms including Lake Street, Morgan Stanley, Cantor Fitzgerald, JP Morgan, and Wells Fargo have maintained or raised their ratings and price targets. NeuroPace is a medical device company with significant revenue growth and market capitalization but faces challenges with net margin, ROE, ROA, and debt management.
December 27, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroPace has seen a positive shift in analyst sentiment with an increased average price target of $9.67, indicating potential stock appreciation. The company's strong revenue growth is a positive sign, but concerns about profitability and debt management persist.
The increase in the average price target and the recent bullish ratings from analysts suggest a positive short-term impact on NPCE's stock price. The strong revenue growth supports this outlook, although the high debt-to-equity ratio and below-average ROE and ROA may temper investor enthusiasm.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100